TEM stock forecast, quote, news & analysis
Tempus AI Inc is a technology company... Show more
Why Tempus AI (TEM) Stock Is Up +27% in the Last 30 Days
Key Takeaways
- Tempus AI shares rose roughly 27% over the trailing 30 days, climbing from a closing price of about $61.25 on August 19 to $77.84 on September 18.
- The advance was fueled by CEO growth commentary at the Morgan Stanley Global Healthcare Conference, a 100,000 whole-genome AI research platform initiative, and fresh Medicare reimbursement estimates for its cancer tests.
- Over the trailing three months, TEM has gained more than 50%, supported by a second-quarter earnings beat and raised full-year revenue guidance.
- Multiple analyst actions, including a Piper Sandler upgrade and a Cantor Fitzgerald Overweight initiation, reinforced the positive narrative.
- Key catalysts ahead include the pending Personalis acquisition, liquid biopsy regulatory timing, and execution on data-licensing contracts.
Tempus AI (TEM) Company Overview and Market Position
Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence to precision medicine. Founded by Eric Lefkofsky, the company operates through two primary business lines: Genomics, which provides next-generation sequencing diagnostics such as comprehensive genomic profiling, and Data and Applications, which licenses multimodal clinical and genomic data and AI models to pharmaceutical and life sciences customers. Its platform combines laboratory testing with one of the largest linked clinical and molecular datasets in oncology, positioning Tempus at the intersection of diagnostics, data infrastructure, and AI. Investors follow the stock for its oncology volume growth, expanding high-margin data business, and a pipeline of regulatory and pricing catalysts.
Tempus AI (TEM) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, Tempus AI climbed approximately 27%, rising from a closing price of $61.25 on August 19 to $77.84 on September 18. The move accelerated sharply late in the period: shares jumped nearly 15% on September 17 to close at $80.36, touching an intraday high of $81.83, before easing 3.1% the following session.
The longer three-month picture is even stronger. From a mid-June close near $50.84, TEM has advanced roughly 53%. That gain was not linear, however. The stock pulled back through July, touching a low near $41.55 on July 29, before rebounding on earnings and regulatory momentum into August and September. The broader trend reflects sustained positive sentiment, punctuated by short-term volatility.
What Drove TEM Stock Price in the Last 30 Days
Several catalysts converged to drive the 30-day advance. At the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, CEO Eric Lefkofsky outlined growth expectations, citing an estimated $80 million to $100 million in annual revenue uplift from solid tumor pricing and a further $250 million to $300 million from a liquid biopsy approval anticipated in the second half of 2027.
Earlier in September, the company announced a multi-year initiative to build a research platform containing 100,000 whole genomes linked to longitudinal clinical, imaging, pathology, and outcome data, with plans to scale toward one million genomes and broaden access through its Tempus Lens environment by mid-2027. The announcement was followed by a rally of more than 30% over the course of a week.
On September 17, shares surged again after reports of estimated Medicare reimbursement rates for the company's cancer products. The move built on a series of favorable analyst actions: Piper Sandler upgraded the stock to Overweight with a $76 target, Cantor Fitzgerald initiated coverage at Overweight with an $80 target, and H.C. Wainwright raised its target to $66. The company also received FDA 510(k) clearance for its ECG PH algorithm, extending its regulated AI product set.
What Drove TEM Stock Performance Over the Last Quarter
The quarterly gain was anchored by strong fundamentals. On July 30, Tempus reported second-quarter 2026 revenue of $382.5 million, up 21.6% year over year, with an adjusted loss of $0.04 per share that beat consensus estimates. Diagnostics revenue rose 20% to $289.3 million, while Data and Applications revenue climbed 28% to $93.2 million, led by 36% growth in data licensing and modeling. Management raised 2026 revenue guidance to roughly $1.60 billion to $1.61 billion, implying about 25% growth.
The quarter also brought regulatory and strategic milestones. Tempus received FDA approval for its tumor-only xT CDx assay, becoming the first laboratory to hold FDA companion diagnostic approval for both tumor-only and tumor-normal comprehensive genomic profiling. The company delivered the first version of its oncology foundation model to AstraZeneca and signed a multiyear data-licensing agreement with BioNTech. It also agreed to acquire Personalis for approximately $1.5 billion to strengthen its molecular residual disease (MRD) franchise, and completed a $460 million convertible notes offering to reduce interest costs.
Trending AI Robots
For traders looking to complement their own research with algorithmic signals, Tickeron's Trending AI Robots page offers a curated view of the platform's artificial intelligence trading bots. Tickeron hosts hundreds of AI-driven bots that trade thousands of tickers, but only top-performing and most relevant strategies appear in this section. The bots vary widely in approach, holding period, and performance metrics, giving users a way to compare strategies rather than relying on a single model. Whether you track healthcare technology names or a broader universe, exploring these automated tools can add a data-driven layer to your market analysis.
TEM Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching Tempus's next quarterly results, expected around November, for evidence that diagnostics volume and data-licensing growth remain on track. The closing of the Personalis acquisition, anticipated in the fourth quarter of 2026 or early 2027, will be a key milestone for the MRD business and its reimbursement economics. The timing and terms of a potential liquid biopsy FDA approval, expected in the latter half of 2027, represent another significant catalyst given the pricing uplift management has outlined. Continued execution on large data contracts with pharmaceutical partners, progress toward adjusted EBITDA targets, and any shifts in Medicare reimbursement policy or competitive dynamics in genomic testing will also shape sentiment. As with any high-growth, currently unprofitable company, valuation sensitivity remains an important consideration.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
TEM's RSI Oscillator sits in overbought zone for 2 days
Watch for a price pull-back in the near future.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TEM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TEM broke above its upper Bollinger Band on September 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on September 15, 2026. You may want to consider a long position or call options on TEM as a result. In 30 of 35 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for TEM just turned positive on September 17, 2026. Looking at past instances where TEM's MACD turned positive, the stock continued to rise in 18 of 22 cases over the following month. The odds of a continued upward trend are 82%.
TEM moved above its 50-day moving average on August 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for TEM crossed bullishly above the 50-day moving average on August 17, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 7 of 7 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.
The 50-day moving average for TEM moved above the 200-day moving average on September 16, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +16.72% 3-day Advance, the price is estimated to grow further. Considering data from situations where TEM advanced for three days, in 108 of 123 cases, the price rose further within the following month. The odds of a continued upward trend are 88%.
The Aroon Indicator entered an Uptrend today. In 46 of 54 cases where TEM Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. TEM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TEM's P/B Ratio (31.746) is slightly higher than the industry average of (7.474). P/E Ratio (39.298) is within average values for comparable stocks, (46.724). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.134). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (8.696) is also within normal values, averaging (6.065).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TEM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry